Genmab | GEN - Des Atouts





Des Atouts Changement Date
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Almirall EUR 2.37B 29.97M 2026-06
Amarin USD 624.36M 21.4M 2026-06
Amgen USD 95.64B 3.14B 2026-06
argenx SE USD 10.03B 1.35B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bayer EUR 107.29B 659M 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Demant DKK 40.03B 951M 2026-06
Exelixis USD 2.49B 99.36M 2026-06
Fresenius Medical Care EUR 31.29B 174.35M 2026-06
Genmab DKK 12.52B 139M 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
GN Store Nord DKK 29.55B 996M 2026-06
GRIFOLS EUR 20.09B 12M 2026-06
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Insmed USD 2.1B 26.7M 2026-06
Lakefront Biotherapeutics EUR 3.35B 21.24M 2026-06
Lonza CHF 18.97B 164M 2025-12
Merck EUR 52.69B 383M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
UCB EUR 18.16B 971M 2025-12